Hardest hit drugs in US price reform

Posted 9 August 2022 PM

Pharmaceutical giants are up in arms over healthcare provisions in the Inflation Reduction Act, passed by the US Senate over the weekend, claiming it will lead to less innovation.

The bill will allow Medicare, government health assistance for those aged over 65, to negotiate prices for 10 high-cost drugs starting in 2026, expanding to include another 15 in 2027 and 60 by 2029.

To see the whole article, please login